Los Angeles – (business wire) — ChromaDex Corp. (NASDAQ: CDXC), a global bioscience company dedicated to healthy aging, has launched consumer nicotinamide adenine dinucleotide (NAD).+) boost supplement, Tru Niagen®was named “Most Popular of the Year” at the China International Natural Health and Nutrition Expo (NHNE), Asia’s largest trade fair for natural health and nutrition products, at the prestigious Nutrition Planet Awards held in Shanghai on September 20, 2022. A certain brand award”. With over 100,000 distributors and retailers, NHNE is considered the best platform to help global manufacturers of health and nutritional products promote their brands and expand their business channels in China, where Tru Niagen is located. I’m here.® It is now sold across borders.
Naigen®Tru Niagen Proprietary Ingredients®is the world’s most efficient and patented NAD.+ It hits the market via its precursors, especially NMN, and is one of the most promising ingredients to enter the healthy aging supplement space.niagen supplementation® Backed by 20 published, peer-reviewed clinical trials, over 200 published scientific studies, and over 30 owned and licensed patents. ChromaDex continues to lead the industry in NAD+ Research by the ChromaDex External Research Program (CERP)TMs) Achieved over 250 Material Transfer Agreements (MTAs) featuring Niagen® and other proprietary ingredients.
“On behalf of ChromaDex, Tru Niagen® Rob Freed, CEO of Chromadex, said: “As a research-driven company with science at its core, this recognition reinforces our intention to become a leading provider of NAD.+ We are boosting our supplements in China and look forward to executing the next phase of growth with Sinopharm Xingsha. ”
As a large-scale professional exhibition of health nutrition and health care products in Asia, NHNE provides excellent brand promotion and product channel expansion services for high-quality enterprises in China and abroad, becoming a priority release platform and top event for health products. Now industry professionals can’t miss.
Sinopharm Xingsha Leads Tru Niagen’s Debut® Industry-leading study of brands through CERP at this year’s NHNETMsincreased presence in cross-border e-commerce channels, and high engagement on several social media platforms in mainland China were instantly recognized by both attendees and exhibitors. In addition to winning the Best Brand Award, Tru Niagen® Sinopharm Xingsha’s 162-meter booth at the exhibition grounds has prime real estate and hosted a celebratory press conference featuring a video of Rob Fried, CEO of ChromaDex.
Pan Lei, General Manager of Sinopharm Xingsha, said: “As you know, China has officially entered an aging society. In 2021, China’s population over the age of 60 will reach 264 million, accounting for 18.7% of the total population. Huge consumption. Group creates a huge market demand.Sinopharm Xingsha adheres to its original intention and mission of “caring for life and health”, always searching for high quality products that can help people aging healthily. and Tru Niagen® Definitely the best choice in this category. ”
Tor Niagen® is currently sold to Chinese consumers on several cross-border online and marketplace platforms, primarily through Tmall and JD, with future expansion led by Sinopharm Xingsha.Tor Niagen® Also available at over 200 Watsons stores in Hong Kong and Macau and over 100 Watsons stores in Singapore. Additionally, ChromaDex, through its wholly-owned subsidiary ChromaDex Asia Pacific Ventures Limited (“JV” or “ChromaDex Asia”), recently announced the formation of a joint venture to commercialize Tru Niagen.® and other products containing Niagen® in China. ChromaDex Asia will enter into a new distribution agreement with Sinopharm Xingsha (“Sinopharm”) upon successful registration of Tru Niagen’s health food.® Take over the cross-border sales contract with the People’s Republic of China.
Naigen® has received regulatory approval for use in dietary supplements by the US FDA.In addition, Niagen® Approved for use in dietary supplements by the European Commission, complementary medicines by the Australian Therapeutic Goods Administration (TGA), medical foods by the Brazilian Health Regulatory Agency (ANVISA), and medical foods by the Food Standards Australia New Zealand (FSANZ). ).Tor Niagen® It is also approved by Health Canada as a natural health product.
For more information on the science behind Niagen, visit® Please visit www.chromadex.com.
About Chromadex:
ChromaDex Corp. is a global bioscience company dedicated to healthy aging. His ChromaDex team, which includes world-renowned scientists, is conducting pioneering research on nicotinamide adenine dinucleotide (NAD+), whose levels decline with age. ChromaDex is the innovator of the NAD+ precursor nicotinamide riboside (NR) and commercialized as the lead ingredient Niagen®Nicotinamide riboside and other NAD+ precursors are protected by ChromaDex’s patent portfolio. ChromaDex maintains a website at www.chromadex.com where ChromaDex regularly posts copies of press releases as well as additional company and financial information.
About Sinopharm Holding and Sinopharm Xingsha:
Sinopharm Xingsha Pharmaceuticals (Xiamen) Co., Ltd. (“Sinopharm Xingsha”) is a subsidiary of the 70-year-old Sinopharm Group Co., Ltd. (“Sinopharm Group”, 01099.HK). Sinopharm Xingsha is the health supplement arm of Sinopharm Group, China’s top 100 nutrition and health consumer brand company, and a major pharmaceutical company in Fujian, China. Xingsha Vitamin D has won the honor of “No. 1 in the Vitamin Category in the Comprehensive Statistical Ranking of His OTC Products in China” for many years in a row. Listed in Shanghai in January 2003 and listed in Hong Kong in September 2009. Currently, it is not only the largest distributor and retailer of pharmaceuticals, healthcare products and medical devices, but also one of China’s leading supply chains. It is also a service provider.The parent company China National Pharmaceutical Group Corporation (“CNPGC”) ranked 109th in the 2021 Fortune Global 500 and Sinopharm Holding ranked 22nd in the 2021 Fortune China 500. For the pharmaceutical distribution segment, Sinopharm Holding has firmly grasped the transforming trend of the industry brought about by volume-based procurement (“VBP”) policy, and by continuously leveraging the economies of scale of its distribution network, has driven the transformation of pharmaceutical distribution.
Forward-Looking Statements:
This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and includes statements relating to NIAGEN. .® It is one of the most promising ingredients to enter the healthy aging supplement arena. Statements that are not statements of historical fact constitute forward-looking statements and often, but not always, “expect,” “anticipate,” “intend,” “estimate,” or “plan.” are identified using words such as “may”, “could”, “likely”, “believe”, “seek”, “could”, “would”, “should”, ” “may”, or the disavowal of such terms or other similar expressions. Risks contributing to the uncertainties in these forward-looking statements include the impact of Includes economic impact. History of operating losses and need for additional funding. Product sales growth and profitability. our ability to maintain sales, marketing and distribution capabilities; changes in consumer perceptions of our products; Reliance on a single or limited number of third party suppliers. risks and uncertainties relating to our business and financial condition; Further information regarding ChromaDex and its potential risk factors affecting the realization of forward-looking statements is available in ChromaDex’s Annual Report on Form 10-K for the fiscal year ended December 31, 2021, Form 10. ChromaDex’s Quarterly Report by -Q. Other documents ChromaDex filed with his SEC. A copy may be obtained from the SEC’s website at www.sec.gov. Readers are cautioned not to place undue reliance on these forward-looking statements. It speaks only as of the date hereof and actual results may differ materially from those implied by these forward-looking statements. All forward-looking statements are qualified in full by this cautionary statement, and ChromaDex undertakes no obligation to revise or update this release to reflect events or circumstances after the date hereof. .
Comments
Post a Comment